Home Guides How to Verify a Tirzepatide Provider
How to Verify a Tirzepatide Provider: The 9-Point Check Before You Pay
A legitimate program names its pharmacy, names its prescriber, requires a real clinical review, publishes total cost at every dose, and is willing to tell you no. Any one of these missing is…
A legitimate program names its pharmacy, names its prescriber, requires a real clinical review, publishes total cost at every dose, and is willing to tell you no. Any one of these missing is a reason to slow down.
On this page
The nine checks
1. The compounding pharmacy is named on the site, not described as 'a licensed US pharmacy'. 2. The prescribing clinician or medical group is named, with a license state you can verify. 3. A clinical review happens before payment, not after. 4. Price at 10 mg and 15 mg is published or given in writing on request. 5. Membership, consultation and shipping fees are disclosed separately and clearly. 6. Cancellation and refund terms are stated before checkout. 7. No 'guaranteed approval' language anywhere. 8. No 'research use only' disclaimer. 9. Cold-chain shipping is described, with a stated policy for what happens if a package arrives warm.
A good provider will decline you
If your history includes medullary thyroid carcinoma, MEN 2, current pregnancy or a history of pancreatitis, a responsible clinician will say no or require further workup. A platform that approves everyone is not being efficient — it is not really reviewing anything.
Third-party credentials worth something
LegitScript certification is used by Google and major payment processors to screen telehealth advertisers and requires an audit. NABP accreditation and PCAB accreditation for the compounding pharmacy are meaningful. State board of pharmacy licensure is the floor, not a distinction.
None of these is legally required for a 503A pharmacy to compound lawfully. Their absence is not proof of a problem — but their presence is independent evidence, which is rare in this market.
Verify the pharmacy yourself
Every state board of pharmacy publishes a license lookup. Search the pharmacy name your provider gave you. Confirm the license is active and that it is licensed to ship into your state. This takes about four minutes and is the single highest-value check on this list.
Common questions
Can I switch from semaglutide to tirzepatide without starting over?
You restart at 2.5 mg tirzepatide regardless of your semaglutide dose, because there is no equivalence between the molecules. Most switchers find re-titration far easier than a first start — roughly 13% report GI symptoms — because GLP-1 receptor adaptation carries over. Take the first tirzepatide dose about seven days after your last semaglutide injection.
Why is some tirzepatide advertised under $100 a month?
Usually one of four reasons: it is the 2.5 mg starter-tier price only, it is an introductory rate that reverts, there is a separate membership fee, or the product is not from a licensed US pharmacy. Ask what you will pay at 10 mg before you enrol.
What is the difference between a 503A and a 503B pharmacy?
A 503A pharmacy compounds for an identified individual patient with a prescription and is licensed by a state board of pharmacy. A 503B outsourcing facility registers with FDA, may compound in bulk without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. Most compounded tirzepatide now flows through the 503A pathway.
How much does tirzepatide cost per month without insurance?
Compounded tirzepatide from licensed US telehealth programs runs roughly $99 to $299 per month depending on the provider and whether the price is flat or scales with your dose. Brand-name Zepbound through LillyDirect self-pay runs about $299 to $449 per month depending on strength. Retail Zepbound without any program is around $1,089.
People also ask about provider red flags
What is provider red flags?
Provider red flags is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does provider red flags apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does provider red flags cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is provider red flags FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.